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Abstract
Background: Chagas disease, caused by Trypanosoma cruzi, is endemic in Latin America and an emerging infectious disease
in the US and Europe. We have shown TcG1, TcG2, and TcG4 antigens elicit protective immunity to T. cruzi in mice and dogs.
Herein, we investigated antigenicity of the recombinant proteins in humans to determine their potential utility for the
development of next generation diagnostics for screening of T. cruzi infection and Chagas disease.
Methods and Results: Sera samples from inhabitants of the endemic areas of Argentina-Bolivia and Mexico-Guatemala were
analyzed in 1st-phase for anti-T. cruzi antibody response by traditional serology tests; and in 2nd-phase for antibody
response to the recombinant antigens (individually or mixed) by an ELISA. We noted similar antibody response to candidate
antigens in sera samples from inhabitants of Argentina and Mexico (n = 175). The IgG antibodies to TcG1, TcG2, and TcG4
(individually) and TcGmix were present in 62–71%, 65–78% and 72–82%, and 89–93% of the subjects, respectively, identified
to be seropositive by traditional serology. Recombinant TcG1- (93.6%), TcG2- (96%), TcG4- (94.6%) and TcGmix- (98%) based
ELISA exhibited significantly higher specificity compared to that noted for T. cruzi trypomastigote-based ELISA (77.8%) in
diagnosing T. cruzi-infection and avoiding cross-reactivity to Leishmania spp. No significant correlation was noted in the sera
levels of antibody response and clinical severity of Chagas disease in seropositive subjects.
Conclusions: Three candidate antigens were recognized by antibody response in chagasic patients from two distinct study
sites and expressed in diverse strains of the circulating parasites. A multiplex ELISA detecting antibody response to three
antigens was highly sensitive and specific in diagnosing T. cruzi infection in humans, suggesting that a diagnostic kit based
on TcG1, TcG2 and TcG4 recombinant proteins will be useful in diverse situations.
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Introduction
The protozoan parasite Trypanosoma cruzi, transmitted by blood-
sucking triatomines, causes Chagas disease, which is a health threat
for an estimated 10 million people, living mostly in Latin America.
More than 25 million people are at risk of the disease [1]. Increasing
travel and immigration has also brought T. cruzi infection into non-
endemic countries, e.g., the U.S., Spain and Australia, where
natural transmission is absent or very low. The congenital and
transfusion- or organ transplantation-related transmissions are
becoming recognized as significant threats in recent decades [2,3].
Diagnosis and treatment of T. cruzi infection has remained
difficult and challenging after 100 years of its identification. This is
because the acute infection, in general produces mild clinical
symptoms, e.g., fever, dyspnea, local swelling at the site of
infection, that are infrequently reported [4]. As a result, acute
exposure when detection of blood parasitemia and treatment is
possible, remain largely unnoticed. Only those who develop severe
acute myocarditis or when an outbreak of T. cruzi infection occurs
may receive early diagnosis and therapeutic treatment [5][6]. In
.95% of human cases, T. cruzi infection remains undiagnosed
until several years later when chronic evolution of progressive
disease results in clinical symptoms associated with cardiac
damage. A conclusive diagnosis of T. cruzi infection then often
requires multiple serological tests, in combination with epidemi-
ological data and clinical symptoms. Unfortunately, after compli-
cated diagnosis, no vaccines or therapies are available to treat the
chronically infected individuals.
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We have, previously, employed an unbiased computational/
bioinformatics approach for screening the T. cruzi sequence
database and identification of potential vaccine candidates [7]. A
strategic analysis of the sequence database led to selection of 71
candidates that were unique to T. cruzi. Of these, eight candidates
(TcG1, TcG2, TcG3, TcG4, TcG5, TcG6, TcG7, and TcG8)
were selected for their ability to induce agglutinating antibody
response in mice [7]. Further studies indicated TcG1, TcG2, and
TcG4 were maximally immunogenic because these were recog-
nized by IgGs in infected mice and dogs (reviewed in [8]), by
CD8+ T cells in infected mice [9], and elicited type I cytokines (e.g.
IFN-c) in mice and dogs [10]. Immunization with candidate
antigens as a DNA vaccine provided a degree of protective
immunity (TcG2 = TcG4.TcG1) that substantially controlled
acute parasitemia after challenge infection in mice and dogs
[10,11]. The delivery of candidate antigens as heterologous
prime/boost vaccines further enhanced the protective efficacy,
evidenced by .80% control of acute parasitemia and tissue
parasite burden and associated inflammation in heart and skeletal
tissue [9,12].
In this study, we investigated the antibody response to the three
candidate antigens (TcG1, TcG2, TcG4) in clinically character-
ized chagasic patients. Our objectives were to evaluate the
antigenicity of the candidate antigens in humans and determine
their utility in generation of improved diagnostics for screening of
T. cruzi infection and disease. Our data demonstrate that the
candidate antigens are recognized by antibody responses in
chagasic patients from two distinct study sites where diverse
strains of the circulating parasites were reported. Further, a
multiplex assay consisting of the mixture of the three antigens was




T. cruzi trypomastigotes (SylvioX10/4, TCI lineage) were
maintained and propagated by continuous in vitro passage in
monolayers of C2C12 cells. Amastigotes were obtained by
incubation of the freshly harvested trypomastigotes in RPMI-
10% FBS medium, pH 5.0 at 37uC, 5% CO2 for 2 h.
Human subjects
Human sera samples used in this study were obtained from
Salta Argentina (located at the border of Bolivia) and Chiapas
Mexico (located on the border of Guatemala) that are known to be
endemic for T. cruzi transmission and human infection. All
procedures were approved by the Institutional Review Boards at
the University of Texas Medical Branch (UTMB), Universidad
Nacional de Salta (UNSa), Argentina, and the Universidad
Auto´noma de Chiapas, Mexico. All sera samples obtained for
the study were analyzed for T. cruzi-specific antibodies by
commercially available kits. Those positive by $ two tests were
considered seropositive (+ve) and those negative for these tests
were considered as seronegative (2ve). All samples were decoded
and de-identified before they were provided for research purposes.
Written informed consent was obtained from all individuals.
In Argentina, all individuals were clinically characterized, and
venous blood samples were collected to obtain plasma or serum.
Clinical data included medical history, physical examination and
subjective complaint of frequency and severity of exertional
dyspnea, electrocardiography (12-lead at rest and 3-lead with
exercise) to reveal cardiac rhythm and conduction abnormalities
and transthoracic echocardiogram to obtain objective information
regarding the left ventricular (LV) contractile function. Chest X-
ray was used to assess cardiomegaly (cardio-thoracic ratio.0.5).
Seronegative and physically healthy subjects exhibiting no history
or clinical symptoms of heart disease were used as controls.
Seropositive chagasic patients were classified according to clinical
exam as follows: Group 0: no echocardiography abnormalities, no
left ventricular dilatations, and $70% ejection fraction (EF)
indicating preserved systolic function, Group I: negligible to minor
EKG alterations, EF: 55–70%, no indication of heart involvement;
Group II: a degree of heart involvement with systolic dysfunction
(EF: 40–55%); and Group III: moderate to severe systolic
dysfunction (EF#40%), left ventricular dilatation (diastolic diam-
eter $57 mm), and/or potential signs of congestive heart failure.
In Mexico, human sera samples were collected within the
framework of a research project on emerging zoonotic diseases
conducted jointly by several institutions, including Chiapas State
University (UNACH), Mexican Social Security Institute (IMSS),
Chiapas Health Institute (ISECH) and UTMB at Galveston [13].
The seropositive subjects generally represented indeterminate/
asymptomatic form of disease. Patients’ detailed information is
presented in Table 1.
1st-phase screening
All sera samples from Salta Argentina were analyzed for T.
cruzi-specific antibodies by the personnel of the Clinical labora-
tories at the San Bernardo Hospital using a Wiener Chagatest-
ELISA recombinant v.4.0 kit (cut-off absorbance at 450 nm:
average of seronegative samples (,0.1) +0.2., i.e. $0.3). Serolog-
ical tests were also done following the specifications of the
commercial IHA test kit (Wiener Chagatest-HAI, positive $1:16
dilution). Those positive by both tests were considered seroposi-
tive, and exposed to T. cruzi infection.
All sera samples from Chiapas Mexico were screened by
epimastigote antigenic lysate-based ELISA, trypomastigote-based
flow cytometry, and Chagas Stat-Pak immuno-chromatograpic
test (Chembio Diagnostic Systems, Medford NY). Those positive
by at least two tests were considered seropositive [13].
Author Summary
Chagas disease is the most common cause of congestive
heart failure related deaths among young adults in the
endemic areas of South and Central America and Mexico.
Diagnosis and treatment of T. cruzi infection has remained
difficult and challenging after 100 years of its identifica-
tion. In .95% of human cases, T. cruzi infection remains
undiagnosed until several years later when chronic
evolution of progressive disease results in clinical symp-
toms associated with cardiac damage. Diagnosis generally
depends on the measurement of T. cruzi–specific antibod-
ies that can result in false positives. A conclusive diagnosis
of T. cruzi infection thus often requires multiple serological
tests, in combination with epidemiological data and
clinical symptoms. In this study, we investigated the
antibody response to TcG1, TcG2, and TcG4 in clinically
characterized chagasic patients. These antigens were
identified as vaccine candidates and shown to elicit
protective immunity to T. cruzi and Chagas disease in
experimental animals. Our data show the serology test
developed using the TcGmix (multiplex ELISA) is a
significantly better alternative to epimastigote extracts
currently used in T. cruzi serodiagnosis or the trypomas-
tigote lysate used in this study for comparison purposes.
Diagnostic Efficacy of T. cruzi Antigens
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2nd-phase screening
Based upon the above analysis, we created sera pools for 2nd
phase screening. Briefly, from Chiapas Mexico, a seropositive pool
(n = 65) and a seronegative pool (n = 34) was included in the 2nd
phase. From Salta Argentina, sera and plasma samples collected in
year 2009 (seropositive, n = 65; seronegative, n = 20) and year
2010 (seropositive, n = 45; seronegative, n = 20) were included. All
blood samples positive for T. cruzi-specific antibodies from Salta
Argentina were analyzed for Leishmania infection by two PCR
approaches. Briefly, total DNA was extracted from blood samples
with a phenol-chloroform mixture, precipitated with ethanol and
dissolved in 20 ml of TE buffer. A PCR reaction was performed
using 1 ml isolated DNA with primer pairs (59-
GTGGGGGAGGGGCGT-TCT-39 and 59-ATTTTACAC-
CAACCCCCAGTT-3) that specifically amplify 120 base pair
product from the conserved region of Leishmania kDNA [14]. The
polymorphism-specific PCR (PS-PCR) allows the identification of
Leishmania species from Argentina, and was performed using the
primer pairs as previously described [15].
To evaluate the specificity of the TcG1-, TcG2-, and TcG4-
based diagnostic ELISA, sera samples from volunteer donors from
Galveston TX, Buenos Aires Argentina, and Toluca Mexico with
no history of residence in the endemic areas, and were healthy
(n = 42, true negative controls) or exhibited cardiomyopathy of
other etiologies (n = 20) were included in the study. Seronegative/
cardiomyopathy patients were identified based clinical exam, and
blood levels of NT-proBNP to be .2000 pg/ml (normal,450 pg/
ml). To examine the cross-reactivity of antigen-based assay, sera
samples from subjects living in Salta Argentina, and diagnosed for
Leishmania infection (n = 35) or certain autoimmune diseases (n = 15)
were also included in the study. Patients were diagnosed for
leishmaniasis (cutaneous, mucocutaneous or visceral) based upon
three criteria (smears and lesions, Montenegro reaction, epidemi-
ology and clinical demonstration) as described in [15], and further
identified to be positive for Leishmania infection by kDNA-specific
PCR and PS-PCR approaches, as above. Briefly, parasitological
analysis was done on smears of dermal scrapings stained with May-
Grunewald Giemsa and examined under a microscope. For
Montenegro skin test, promastigote protein lysates (4 mg/100 ml)
of Leishmania braziliensis were injected intradermally on the ventral
forearm of the patients, and indurations $5 mm in diameter,
observed 48 h after the injections were considered reactive. Clinical
features included the presence of compatible tegumentary injuries
with ulcerative, nodulous, papulous cutaneous or mucocutaneous
lesions and a congruent epidemiological history. Patients’ informa-
tion is presented in Table 1.
Sera samples were analyzed for IgG antibody levels by using
TcG1-, TcG2-, TcG4-based ELISA. Recombinant TcG1, TcG2
and TcG4 proteins were purified from E. coli. The nucleotide
sequences of TcG1, TcG2 and TcG4 antigens have previously
been submitted to GenBank under accession numbers AY727914,
AY727915 and AY727917, respectively [7]. The cDNAs encoding
TcG1 (1–166 amino acids), TcG2 (1–220 amino acids), and TcG4
(1–92 amino acids) were cloned in pCR2.1 T/A vector, and then
Table 1. Characterization of the subjects included for screening of TcG1-,TcG2-, and TcG4-specific antibody responses in this
study.
Clinical characterization Enrolled subjects (numbers) Age range in years Sex Males (%)
Salta, Argentinaa
Seropositive for T. cruzi-specific antibodiesb
Chagasic 0 n = 54 19–75 44 (40%)
Chagasic I n = 30
Chagasic II n = 17
Chagasic III n = 9
Seronegative for T. cruzi-specific antibodies
Healthy, no disease n = 40 18–55 19 (48%)
Leishmaniasis n = 35 18–62 25 (71%)
Autoimmune diseases n = 15 NA NA
Chiapas, Mexicoc
Seropositive for T. cruzi-specific antibodies
Chagasic 0-I n = 65 18–73 29 (45%)
Seronegative for T. cruzi-specific antibodies
Healthy, no disease n = 34 18–73 15 (45%)
Non-endemic areasd
Seronegative, healthy, no disease n = 42 18–55 16 (38%)
Seronegative, other Cardiomyopathy n = 20 42–75 12 (60%)
aSubjects in Argentina were screened for T. cruzi-specific antibodies by Wiener Chagatest-ELISA and Wiener Chagatest-HAI kits. Clinical exam included physical exam,
electrocardiography and echocardiography. Confirmation of leishmaniasis was obtained by parasitological test, Montenegro reaction, clinical demonstration, and two
PCR approaches. One of the seropositive patient presenting acute infection was referred for chemotherapeutic treatment with Benznidazole.
bFive of the seropositive/chagasic subjects from Argentina were positive for Leishmania infection, determined by two PCR approaches.
cSera samples from Chiapas Mexico were screened by epimastigote antigenic lysate-based ELISA, trypomastigote-based flow cytometry, and Chagas Stat-Pak immuno-
chromatograpic test.
dSeronegative subjects from non-endemic areas were screened for T. cruzi-specific antibody response using T. cruzi trypomastigote lysate as antigen source in ELISA
assays. Seronegative/cardiomyopathy patients were identified based upon blood levels of NT-proBNP to be .2000 pg/ml (normal,450 pg/ml).
N/A: not available.
doi:10.1371/journal.pntd.0002018.t001
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sub-cloned in to pET-22b plasmid (Novagen, Gibbstown, NJ) such
that the encoded proteins were in-frame with a C-terminal
polyhistidine tag. All cloned sequences were confirmed by
restriction digestion and sequencing at the Recombinant DNA
Core Facility at UTMB. The pET22b plasmids containing TcG1,
TcG2 or TcG4 were transformed in BL21 (DE3) pLysS competent
cells (Invitrogen, Carlsbad CA) and recombinant proteins purified
using the polyhistidine fusion peptide metal chelation chromatog-
raphy system (Novagen) [9]. After purification, proteins were
dialyzed to remove contaminant particles, and endotoxins, and
stored at 280uC till further use. Culture-derived parasites (70%
trypomastigotes/30% amastigotes) were lysed by repeated freeze-
thaw in PBS (109/ml) and used as a source of T. cruzi total antigen
for positive control [10].
Flat bottom, high-binding, 96-well plates (Greiner bio-one) were
coated overnight at 37uC with 100-ml/well of recombinant
antigens (0.5 mg each antigen/well, individually or in combination)
or T. cruzi total lysate (56105 parasite equivalents/well). Plates
were blocked for 2 h at 37uC with 200-ml/well of 5% non-fat dry
milk (NFDM) in PBS, washed with PBS-0.05%Tween-20 (PBST)
twice, and PBS once, and then incubated for 2 h with test sera
(100-ml/well) added in triplicate in 2-fold dilutions. Plates were
then washed and incubated at room temperature for 30 min with
100-ml/well of horseradish peroxidase-labeled goat anti-human
IgG (1:5000 dilution in PBST-1% NFDM), and color was
developed for 5 min with 100 ml/well of Sure Blue TMB substrate
(Kirkegaard & Perry Laboratories). The colorimetric reaction was
stopped with 2N H2SO4, and absorbance measured at 450 nm
using SpectraMax M5 Microplate Reader (Molecular Devices).
The sensitivity of the antigen-based ELISA (2nd phase) was
determined by calculating the percentage of chagasic samples that
exhibited reactivity with recombinant proteins out of the total
samples previously categorized as seropositive based on 1st phase
screening with commercially available kits. The data from antigen-
based ELISA analysis of sera samples from healthy individuals,
other cardiomyopathy and leshmaniasis patients was utilized to
calculate the specificity of the assay as follows: [ number of sera
samples analyzed – number of sera samples that exhibited false
positive reaction or cross-reactivity with TcG1, TcG2 or TcG4/
number of sera samples analyzed]6100.
Data analysis
All samples were analyzed in duplicate and assayed at least
twice for all experiments. Box plots and dot plots were made using
Sigma Plot 12.0 and GraphPad Prism 5 software, respectively, and
statistical analysis was conducted using SPSS v.18 software.
Results were analyzed using Student’s t test for statistical
evaluation of mean values for experimental and control samples,
and the level of significance was taken at a,0.05. Pearson’s
correlation analysis was performed to determine the relationship
between predictive efficacies of the antibody response to selected
antigens in diagnosis of disease severity. Seropositivity rates for
anti-T. cruzi antibodies in different tests, and their confidence
intervals [CIs], were calculated using the mid-P 95% confidence
interval (95% CI) using Epi Info (version 6.0) software.
Results
To proceed with sample analysis, we optimized ELISA
components by cross-titration, using a pool of known positive
and negative controls (1:20–1:1600 dilutions). The optimal sera
and HRP-conjugated secondary antibody dilutions providing
maximum signal-to-noise ratio were determined to be 1:50 and
1:5,000, respectively, and used in all further investigations. The
variations in reactivity of negative and positive sera among
different assays and plates of the same experiment ranged from 3–
12%.
We, first, monitored the antigenicity of TcG1, TcG2, and TcG4
using sera samples collected from volunteers enrolled in the study
in Argentina in year 2010. Samples were stored at 280uC just
after collection, and thawed when utilized. The negative sera
samples (n = 20) from the endemic area near Argentina-Bolivia
border exhibited low reactivity for TcG1, TcG2, and TcG4,
similar to that noted for confirmed negative controls (n = 42) from
non-endemic areas (TcG1: 0.21660.035 versus 0.21160.048,
TcG2: 0.24060.04 versus 0.23060.044, TcG4: 0.22560.041
versus 0.25260.038, expressed as mean absorbance 6 SD). In
comparison, a 4-fold, 2.75-fold, and 2.65-fold increase in sera
levels of antibody response to TcG1, TcG2, and TcG4,
respectively, was noted in previously characterized seropositive
subjects (n = 45) from Argentina-Bolivia border (TcG1:
0.8160.33, TcG2: 0.6660.20, TcG4: 0.5760.09, expressed as
mean absorbance 6 SD, p,0.001 for all, Fig. 1.A–C). The sera
levels of antibodies to TcG1, TcG2, and TcG4 were above the
meanseronegative level in 62.2%, 66.6% and 75.5% of the 1
st-phase
seropositive subjects. When analyzing plasma samples from the
same individuals, we noted a 3.34-fold, 2.4-fold and 2.3-fold
increase in plasma levels of antibodies to TcG1, TcG2 and TcG4
in seropositive subjects as compared to seronegative controls
(TcG1: 0.7760.21 versus 0.2060.05, TcG2: 0.6560.12 versus
0.2160.057, TcG4: 0.6760.09 versus 0.2060.048, expressed as
mean absorbance 6 SD, p,0.001 for all, Fig. 1.D–F). The plasma
levels of antibodies to TcG1, TcG2, and TcG4 were above the
meanseronegative levels in 71.1%, 77.7% and 80% of the 1
st-phase
seropositive subjects. These data suggested that a) TcG1, TcG2
and TcG4 are recognized by antibody responses elicited in human
patients infected by T. cruzi, and b) both plasma and sera samples
can be utilized to monitor the antibody response.
We then analyzed the plasma samples that were collected in
2009, and characterized as seropositive (n = 65) and seronegative
(n = 20) by 1st-phase serology tests. These samples were subjected
to two cycles of freezing/thawing during the two-year storage. Our
data showed a 6.72-fold, 2.4-fold and 2.9-fold increase in plasma
levels of antibodies to TcG1, TcG2 and TcG4 in seropositive
subjects as compared to seronegative controls (TcG1: 1.6660.55
versus 0.20460.05, TcG2: 0.6960.13 versus 0.23960.039, TcG4:
0.7560.20 versus 0.22760.05, expressed as mean absorbance 6
SD, p,0.001 for all, Fig. 1.G–I). The plasma levels of antibodies
to TcG1, TcG2, and TcG4 were above the meanseronegative level in
61.5%, 64.6% and 81.5% of the seropositive subjects. These
results suggest that antibody response to TcG1, TcG2, and TcG4
is stable, and field samples can be utilized to examine antigenicity
of the selected candidates in large-scale population studies.
Overall, the data presented in Fig. 1 also indicate that TcG1,
TcG2 and TcG4 are expressed by T. cruzi isolates circulating in
the endemic areas at the Argentina-Bolivia border.
It is important to know if antibody recognition of the three
antigens can be expanded for diagnosis of T. cruzi infection in
other countries where different isolates are suggested to be present
in domestic and sylvatic cycle of parasite circulation. For example,
in Argentina and neighboring countries in South America, TCII
isolates are predominantly identified in peripheral blood of
seropositive patients, though molecular studies have revealed the
presence of TCI parasites also in heart biopsies of chronic chagasic
patients [16,17,18]. In Mexico and Guatemala, TCI is dominantly
found in epidemiological evaluation of infected triatomines as well
as in blood samples from acute and chronic chagasic cardiomy-
opathy patients [19,20]. We, therefore, monitored the antigenicity
Diagnostic Efficacy of T. cruzi Antigens
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of TcG1, TcG2, and TcG4 in human sera samples from Mexico-
Guatemala border area that were characterized as seropositive
(n = 65) and seronegative (n = 34) by 1st-phase serology tests. Our
data showed 6.72-fold, 2.4-fold and 2.9-fold increase in sera levels
of antibodies to TcG1, TcG2 and TcG4 in seropositive samples as
compared to that noted in seronegative healthy controls (TcG1:
0.760.25 versus 0.21160.047, TcG2: 0.6460.22 versus
0.2560.05, TcG4: 0.6560.20 versus 0.21260.048, expressed as
mean absorbance 6 SD, p,0.001 for all, seropositive versus
seronegative, Fig. 2). The sera levels of antibodies to TcG1, TcG2,
and TcG4 were above the meanseronegative level in 69.2%, 76.9%
and 72.3% of the seropositive subjects from Mexico. These data
demonstrate that TcG1, TcG2 and TcG4 are antigenic, and
recognized by antibody responses in chagasic patients from
Mexico, and suggest that the three antigens are expressed by T.
cruzi isolates circulating in Mexico-Guatemala border area.
Next, we determined if the three candidate antigens can be
utilized together to improve the diagnosis of exposure to T. cruzi. For
this, we coated the 96-well plates with either the mixture of TcG1,
TcG2 and TcG4 (0.5 mg/well each) or T. cruzi trypomastigote lysate
(TcTL, 26105 parasite equivalent), and monitored the antibody
response by ELISA under similar experimental conditions. When
antibody response was captured using the TcGmix, the seronegative
controls from the non-endemic areas exhibited a mean absorbance
6 SD of 0.22560.039. Using the controls’ mean absorbance+2SD,
our data validated 40 of the 45 sera samples (88.8%) from
Argentina, characterized as seropositive in 1st-phase screening in the
year 2010, were seropositive for TcGmix-specific antibodies (mean
absorbance6 SD: 0.7360.17, maximum OD: 1.2, Fig. 3A). One of
the volunteer previously characterized as seronegative exhibited
anti-TcGmix antibody response above the meanseronegative level.
Similarly, the plasma detection of antibody response to TcGmix
identified 102/110 of the seropositive subjects (92.7%) identified in
1st-phase screening in the years 2009 and 2010 (Fig. 3B,C). In
comparison, when plates were coated with TcTL to capture anti-T.
cruzi antibodies, the seronegative true controls from non-endemic
areas, exhibited a mean absorbance 6 SD value of 0.23360.044
(Fig. 3C,E). Using the mean absorbance for controls +2 SD as a cut
off, our data validated 97.7–100% sera and plasma (year 2010) and
96.9% plasma (year 2009) samples characterized as seropositive in
Figure 1. Antigenicity of TcG1, TcG2 and TcG4 in inhabitants of Salta Argentina. Sera (A–C) and plasma (D–I) samples obtained in year
2010 (A–F) and year 2009 (G–I) from volunteers in Salta Argentina were identified as seropositive (+ve) or seronegative (2ve) in 1st-phase screening
by using conventional approaches. The 2nd-phase screening for antigen-specific antibody response was conducted by an ELISA using the
recombinant TcG1, TcG2 and TcG4 proteins. Data (mean of four observations from each sample) are presented as box plot. The horizontal lines of the
box (bottom to top) depict the lower quartile (Q1, cuts off lowest 25% of the data), median (Q2, middle value), and upper quartile (Q3, cuts off the
highest 25% of the data). The lower and upper whiskers depict the smallest and largest non-outlier observations, respectively, and solid dots
represent the outliers. The spacing between the different parts of the box indicates the degree of dispersion (spread). Standard deviation for all
samples was ,12%.
doi:10.1371/journal.pntd.0002018.g001
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1st-phase screening in Argentina were also positive for TcTL-
specific antibodies; the mean absorbance 6 SD for the positive
population was 1.160.6 (year 2009) and 0.7360.08 (year 2010)
with the highest value being 2.5 and 0.98, respectively (Fig. 3B,D,F).
One of the volunteer previously characterized seronegative
exhibited anti-TcTL antibody response.
To validate that diagnostic potential of the TcGmix based
ELISA is not restricted to samples from Argentina, we monitored
the antibody response using sera samples collected in Mexico. Of
the 65 samples characterized as seropositive in 1st-phase screening,
58 (89.2%) and 63 (96.9%) exhibited reactivity when plates were
coated with TcGmix and TcTL antigens, respectively (Fig. 4). The
mean absorbance 6 SD for the antibody response to TcGmix and
TcTL in the positive population positive population was
0.7560.14 (max: 1.2) and 0.8760.4 (max: 2.6), respectively, the
difference between the two values being observed non-significant.
No significant difference was observed when either plasma or sera
were used as the source of antibodies.
Five of the 110 seropositive/chagasic subjects from Argentina
exhibited reactivity for Leishmaina-specific antibodies and were
likely infected with both pathogens. To examine if the antigen-
based ELISA is specific for T. cruzi detection, we performed
recombinant antigens-specific ELISA using the sera samples from
non-chagasic individuals (total 112), including leishmaniasis
patients (n = 35), volunteer donors with cardiomyopathy (n = 20)
and autoimmune diseases (n = 15) of other etiologies, and healthy
donors from non-endemic areas (n = 42), and calculated the
specificity of the antigen-based ELISA. Sera samples from
Figure 2. TcG1, TcG2 and TcG4 are recognized by antibody response in human subjects from Mexico. Sera samples obtained from
volunteers living in the endemic areas of Chiapas Mexico were characterized as seropositive (+ve) and seronegative (2ve) by whole-parasite antigen
based serology tests in the 1st phase. The TcG1 (A), TcG2 (B) and TcG4 (C) specific antibody response was measured by ELISA, and data are presented
as box plot (details in Fig. 1).
doi:10.1371/journal.pntd.0002018.g002
Figure 3. TcGmix-based ELISA provides superior efficacy in
identifying exposure to T. cruzi infection among inhabitants of
Salta Argentina. Sera (A&B) and plasma (C–F) samples, characterized
as seropositive (+ve) and seronegative (2ve) by conventional
approaches, were submitted to multiplex ELISA using the mixture of
recombinant TcG1, TcG2 and TcG4 proteins for capturing the antigen-
specific antibody response (A,C,E). Shown are the antibody response
captured using the T. cruzi trypomastigote lysate (TcTL) as a source of
crude antigen (B,D,F) for comparison purpose.
doi:10.1371/journal.pntd.0002018.g003
Figure 4. TcGmix-based ELISA was effective in diagnosing
exposure to T. cruzi infection among inhabitants of Chiapas
Mexico. Sera samples obtained from volunteers living in the endemic
areas of Chiapas Mexico were characterized as seropositive (+ve) and
seronegative (2ve) by whole-parasite antigen based serology tests in
the 1st phase. Shown are the antibody response captured by an ELISA
using mixture (TcGmix) of recombinant TcG1, TcG2 and TcG4 proteins
(A) or T. cruzi trypomastigote lysate (TcTL) (B) as a source of antigen.
doi:10.1371/journal.pntd.0002018.g004
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leishmaniasis patients (n = 35) exhibited very low reactivity for
TcG1, TcG2, and TcG4, similar to that noted for sera samples
from confirmed negative controls from non-endemic areas
(TcG1: 0.1860.04 versus 0.2160.048, TcG2: 0.1560.06 versus
0.23060.044, TcG4: 0.23260.05 versus 0.25260.038, expressed
as mean absorbance 6 SD). Likewise, sera samples from patients
exhibiting symptoms of cardiomyopathy of non-chagasic etiology
or autoimmune diseases showed reactivity to TcG1, TcG2, and
TcG4 below the cut-off threshold values derived from healthy/
seronegative controls. The specificity for TcGmix was highest
(98%), followed by TcG2 (96%), TcG4 (94.6%), TcG1 (93.6%)
and TcTL (77.8%), determined by detection of false positive
signal for 2, 4, 6, 7 and 25 of the samples, respectively, out of the
total 112 samples from non-chagasic individuals that were
submitted for antigen- and TcTL-based ELISA. These data
indicated that the recombinant antigens were highly specific for
the detection of anti-T.cruzi antibodies than the whole parasite
(trypomastigote) lysate, and exhibited no cross-reactivity to
Leishmania-specific antibodies.
Pearson correlation analysis was employed to identify correla-
tion between antigen-specific antibody response and disease state
including the data derived from seronegative/healthy controls and
seropositive/chagasic subjects. For this, seronegative/healthy
subjects were labeled as 0, and patients classified as 0, I, II and
III (Materials and Methods) were labeled as 1, 2, 3, and 4,
respectively. Antibody response was titrated using 2-fold sera
dilutions (1:50–1:1600). We observed no significant correlation
between the anti-TcG2, anti-TcG4, anti-TcGmix and anti-TcTL
antibody titration curves and clinical disease category in any of the
patient population (data not shown). The representative correla-
tion data from sera levels of anti-TcGmix and anti-TcTL antibody
response (1:50 dilutions) and clinical disease category for the
clinically characterized Argentine patients enrolled in the study is
shown in Fig. 5. It is worth noting that TcGmix-specific antibodies
exhibited a clear downward trend with patients’ disease severity,
indicating that presence of antibodies for TcG1, TcG2, and TcG4
is protective during progressive Chagas disease (Fig. 5A). No clear
trend or correlation was observed for TcTL specific antibody
response and disease severity in any of the patient population
(Fig. 5B).
Discussion
Serological diagnosis of Chagas disease is frequently based on
tests such as enzyme-linked immunoassays (EIAs), indirect
immunofluorescence assays, and indirect haemagglutination assays
(IHAs). Most of these serological tests, including one recently
licensed by the United States Food and Drug Administration for
use as a blood screening test in the U.S. [21], use crude or semi-
purified T. cruzi epimastigote forms as the antigen, the stage that is
present in insects but not in infected humans. Overall, the current
diagnostics fail to provide a high degree of sensitivity and
specificity, requiring use of multiple tests for diagnosis of T. cruzi
infection [22]. Further, most of the currently available kits produce
questionable results when used for donors with low titers [23]. The
absence of a true gold standard makes it difficult for the medical
practitioners to provide proper treatment as not all cases are
properly identified and treatment response cannot be accurately
monitored. Accordingly, World Health Organization has empha-
sized the need to employ defined antigens for improved
serodiagnosis of T. cruzi infection [24]. However, before an
antigen can be used for diagnostics, several criteria should be met:
(i) the selected candidate antigen(s) should be expressed in isolates
circulating in different areas of endemicity, (ii) antigens should be
highly immunogenic in populations with different genetic back-
ground, (iii) they should be absent from other pathogens to prevent
cross-reactivity, and (iv) easily expressed and purified from
traditional protein expression systems (e.g. E. coli) to ensure
reproducibility and quality control [25]. Because of the complexity
involved in antigen selection and testing, limited progress has been
made towards the development of antigen-based kits for the
diagnosis of T. cruzi infection.
Keeping the above guidelines in mind, we believe that TcG1,
TcG2 and TcG4 are ideal candidates for the development of
diagnostic assays. One, these antigens were previously shown to be
expressed in infective and intracellular forms of clinically relevant
multiple isolates of T. cruzi [7]. Two, the small size of the three
antigens (TcG1: 18.4 kDa, TcG2: 24 kDa, TcG4: 10 kDa) allows
reproducible high-yield purification of the proteins from E. coli
(0.5–1.0 g/L) and is amenable to large-scale production. Three,
the presence of multiple 12-mer B cell epitopes of high specificity
(Table 2) suggests that these antigens will be immunogenic,
Figure 5. Pair-wise correlation analysis. Shown is pair-wise correlation analysis of antibody response to TcGmix (A) and TcTL (B) with clinical
disease category in patients enrolled in the study from Argentina-Bolivia border area. For this, seronegative/healthy subjects were labeled as 0, and
patients classified as 0, I, II and III (Materials and Methods) were labeled as 1, 2, 3, and 4, respectively. Dots, individual subjects.
doi:10.1371/journal.pntd.0002018.g005
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recognized by B cells of the immune system, and elicit antibody
response. Indeed, we have found that TcG1, TcG2 and TcG4 are
recognized by antibodies elicited in infected dogs and mice [9,11].
The diagnostic potential of the three antigens in humans was
evident from our analysis of a panel of sera or plasma from chronic
chagasic patients from Argentina-Bolivia and Mexico-Guatemala
border areas. T. cruzi strains of lineages TCV (IId), TCII (IIb) and
TCI were identified in seropositive chagasic patients from
Argentina/Bolivia (Patricio Diosque and Monge Rumi, personal
communication), and of lineage TCI in seropositive subjects from
Mexico/Guatemala (unpublished results). Others have document-
ed the predominance of TCII isolates in peripheral blood of
seropositive patients from South America [16,17,18] and TCI in
Mexico and Guatemala [19,20]. Thus, our data presented in
Figs.1, 2, 3, 4 suggest the diagnostic kit developed using TcG1,
TcG2 and TcG4 will be useful in identifying T. cruzi circulation
and transmission in South, Central and North America.
It is important to note that TcG1, TcG2 and TcG4, when used
individually, exhibited 93.6–96% specificity in detecting anti-T.
cruzi antibody response that was in the range for other
recombinant proteins (e.g. TSSA, CP1 and CP2) proposed for
Chagas disease immunodiagnosis [26,27]. However, 98% speci-
ficity of the TcGmix-based ELISA was much higher than that
observed for single antigens in this study or other recombinant
antigens in other reports [26,28]. Further, TcGmix specificity at
98% was significantly better than that observed with T. cruzi
trypomastigote-based ELISA (77.8%) that is not desirable because
culturing of human-infective form of the pathogen requires special
facilities, technology, and expertise.
Another major concern that is generally not taken into
consideration when one is using serological tests for Chagas
disease is the potential frequency of cross-reactivity. In some areas
of endemicity in Central America and Brazil, where T. cruzi and
the nonpathogenic protozoan Trypanosoma rangeli can be found
infecting the same vectors and vertebrate hosts, cross-reactivity has
been proposed to contribute to miscalculated higher percentage of
T. cruzi transmission and misdiagnosis of patients may have severe
health-related and economic consequences [29,30]. Others have
documented the crude antigen-based serodiagnostic kits exhibit
cross-reactivity between sera of patients infected with T. cruzi and
sera of patients infected with Leishmania spp. [31,32,33]. In our
study, homology searches suggested that only TcG1 is similar to a
ribosomal protein of other trypanosomes (.90% identical) while
TcG2 and TcG4 exhibited no clear paralog in the public
databases (Fig.S1). Thus, to rule out the possibility of cross-
reactivity with Leishmania, we have screened sera samples from
confirmed leishmaniasis patients for antibody cross-reactivity to
TcG1, TcG2 and TcG4. Our data clearly showed that the three
antigens exhibited no cross-reactivity to antibodies generated in
cutaneous, mucocutaneous and visceral leishmaniasis patients,
providing evidence that the antibody response to TcG1, TcG2 and
TcG4 was solely directed by exposure to T. cruzi infection.
Finally, TcGmix-ELISA performed at a higher potency in
discriminating weakly positive samples from background, demon-
strated statistically by calculating the quotient of measured optical
density values divided by the cutoff values. Only 12 of all the
seropositive samples had a quotient smaller than 2.0 in the
TcGmix-ELISA whereas TcG1-, TcG2- TcG4 and TcTL-based
ELISA resulted in 18, 16, 14 and 16 samples below the mean
value. This potency will facilitate diagnosis because weakly positive
results routinely need to be confirmed by alternative assays. Thus,
based upon high sensitivity (93%) and specificity (98%) to sera
from chagasic patients from different endemic countries, we
surmise that TcGmix-based ELISA can serve as a single assay to
determine the T. cruzi status of a given blood sample, and diagnose
Chagas disease. We plan to further standardize the assay for large-
scale screening and establishing the prototype assay for commer-
cial use of the selected antigens for diagnostic kits.
Table 2. B cell epitopes in candidate antigens.
Protein name (Acc# in
Genbank) Protein (aas) Predicted B cell epitopes
Position Epitope Score














TcG4 (AAU47268.1) 91 39 MWVEHQRRLRQE 0.973
1 MSAKAPPKTLHQ 0.958
74 IPTIVPKELHEL 0.542
Linear B cell epitopes (12 amino acid lengths) were predicted using a BCPred tool (http://ailab.cs.iastate.edu/bcpreds/).
doi:10.1371/journal.pntd.0002018.t002
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The immune interactions necessary to eradicate T. cruzi
parasites are extremely complex and require both humoral and
cell-mediated components of the immune system. Previous
experimental studies and a few studies in humans indicate that
antibodies are able to kill T. cruzi in the presence of phagocytic
cells, such as macrophages. Others have shown in B cell knockout
mice or mice depleted of B cell function, the pivotal role of
antibody molecules in attaining resistance to T. cruzi infection and
Chagas disease (reviewed in [34]). In this study, the mean antibody
response to TcG1, TcG2 and TcG4 (individually or in combina-
tion) exhibited a downward trend in correlation to clinical disease
severity suggesting that antibody response to the candidate
antigens was protective, though further studies with larger patient
population will be required to validate the significance of this
observation. The experimental data indicating the up regulation of
IgG1 antibodies specific to TcG1, TcG2 and TcG4 [9,11] suggest
that isotypes related to up regulation of opsonization, cell
dependent cytotoxicity and activation of classical complement
pathway are elicited by the candidate antigens, and might be
present in significant levels in seropositive/chagasic individuals.
Considering that the three antigens have been shown to be located
on plasma membrane of trypomastigote/amastigote stages of
T. cruzi by flow cytometry [7], we predict that these will be
available as a target to antibody-dependent cell cytotoxicity
effector mechanisms mediated by IgG1. Indeed, TcG1, TcG2
and TcG4 have been shown to elicit potent trypanolytic antibodies
in accordance with the intensity of the surface expression of these
antigens in infective and intracellular stages (as compared to eight
others tested in similar experiments) [7]. In addition to IgG1,
candidate antigens elicited IgG2b known to drive the type 1
adaptive immunity in experimental mice and dogs [9,11]. High
levels of candidate antigens-induced IgG2b in vaccinated mice
were linked to complement-dependent trypanolytic activity [9].
Patients in the indeterminate phase display higher levels of lytic
antibodies compared with patients with chagasic heart disease
indicating an association between the presence of lytic antibodies
and a protective response in chronic patients [35,36]. This was
also evidenced by absence of lytic antibodies in patients treated
with anti-parasite drugs that displayed negative hemocultures for
over ten years [37]. Based upon these observations, we consider
that activation of IgG2a (along with IgG1) will be an important
attribute that contributes to host protection against T. cruzi
infection and Chagas disease when TcG1, TcG2 and TcG4 will be
tested as vaccine candidates in humans.
In summary, this is the first report identifying the antigenicity of
TcG1, TcG2 and TcG4 in humans. We have concluded that the
three candidate antigens are recognized by IgGs in sera samples of
seropositive/chagasic patients. Further, the candidate antigens
were represented in diverse strains of T. cruzi as the sera samples
from two different endemic areas from the South, Central and
North America recognized the antigens at the same rate. Our data
show the serology test developed using the TcGmix is a significantly
better alternative to epimastigote extracts currently used in T. cruzi
serodiagnosis or the trypomastigote lysate used in this study for
comparison purposes. TcGmix ELISA was .98% specific and
93% sensitive, was not discriminatory of sex, age or geographic
location of the individuals, performed at a higher potency in
identifying weakly positive samples, and, thus, has a potential to
serve as a single assay for the diagnosis of T. cruzi infection. Future
studies with large cohorts of patients will be required to determine
if immunological responsiveness to the three antigens detects with
high confidence the chronicity of infection, severity of disease, and
effectiveness of treatment etc.
Supporting Information
Figure S1 TcG1, TcG2 and TcG4 homology to proteins
in other trypanosomatids. Homology searches were per-
formed using the NCBI BLASTP against nr database to identify
homology for TcG1, TcG2 and TcG4 proteins of T. cruzi in other
trypanosomatids (e.g. Leishmania spp, T. brucei, T. congolense, T. vivax).
Shown are the results from maximum observed homology.
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